Physician profile
Cheyenne Quach
NPI 1184350597
$2,721.24
in general payments reported to CMS, 2019-2025
26 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.75 · 2023: $1,599 · 2024: $965 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663 · Education: $29.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.45 |
| Education | $29.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $390.21 | 2023-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $329.71 | 2023-2024 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $286.67 | 2023-2024 | |
| Novo Nordisk INC | $237.85 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $207.36 | 2023-2024 | Repatha, Otezla, Prolia |
| Mannkind Corporation | $183.55 | 2023-2024 | Afrezza |
| Regeneron Healthcare Solutions, INC. | $138.34 | 2023-2024 | Dupixent |
| Abbott Laboratories | $127.74 | 2023-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $103.44 | 2023-2024 | Fasenra, Tezspire, Breztri |
| Xeris Pharmaceuticals, INC. | $91.11 | 2023-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.96 | 2023-2024 | Jardiance, Synjardy |
| Radius Health, INC. | $75.80 | 2023 | Tymlos |
| Corcept Therapeutics | $69.60 | 2023-2024 | Korlym |
| Dexcom, INC. | $67.76 | 2023-2024 | Dexcom G6 Transmitter |
| Organon LLC | $59.34 | 2025 | Ganirelix Acetate, Follistim Aq, Nexplanon |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $43.43 | 2023-2024 | |
| Abbvie INC. | $34.09 | 2024 | |
| Averitas Pharma INC. | $30.81 | 2023 | Qutenza |
| Amryt Pharma Holdings LTD | $28.75 | 2022 | |
| Kyowa Kirin, INC. | $28.31 | 2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $28.12 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $24.69 | 2023 | Airduo Digihaler |
| Exact Sciences Corporation | $18.18 | 2023 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $13.64 | 2023 | Strensiq |
| Halozyme INC | $13.45 | 2023 | |
| Antares Pharma, INC. | $13.33 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheyenne Quach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.